Alnylam Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 2834 http://www.alnylam.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

Here’s What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY) - Jun 19th, 2019 6:09 pm
Alnylam Completes Enrollment in Phase III Study of Lumasiran - Jun 18th, 2019 7:58 am
See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. - Jun 18th, 2019 6:06 am
Alnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy - Jun 18th, 2019 6:00 am
Regeneron (REGN) Presents Positive Data on Lymphoma Candidate - Jun 17th, 2019 7:12 am
Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1) - Jun 17th, 2019 5:00 am
Why Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is A Financially Healthy Company - Jun 14th, 2019 12:50 pm
Boston-area biopharm firm has big plans in Philadelphia - Jun 13th, 2019 10:03 am
Alnylam to Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society (PNS) Annual Meeting and the 5th Congress of the European Academy of Neurology (EAN) - Jun 13th, 2019 6:00 am
Alnylam Completes Rolling NDA Submission to FDA for Givosiran - Jun 6th, 2019 1:28 pm
Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria - Jun 5th, 2019 5:00 am
Alnylam Initiates Phase I Study on Hypertension Candidate - Jun 3rd, 2019 2:48 pm
Why Is Alnylam (ALNY) Down 16.8% Since Last Earnings Report? - May 31st, 2019 7:31 am
Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension - May 31st, 2019 5:00 am
Alnylam to Webcast Presentations at Upcoming June Investor Conferences - May 30th, 2019 2:00 pm
BioMarin Announces Data on Hemophilia Candidate, Shares Fall - May 29th, 2019 8:52 am
Alnylam Announces New Leadership Appointments - May 29th, 2019 6:00 am